

Oral GLP1 in CKD on a SGLT2i with or without T2DM (AZ-ELEVATE)

Study location [BCDiabetes: 400 - 210 West Broadway, Vancouver V5Y 3W2](#)

Principal Investigators Dr. Tom Elliott

Subinvestigators : Dr Dale Clayton and Dr Dae Won (David) Lee

SC & Primary Contact Marla Inducil MD P: 604-628-7253 x 7011 : minducil@bcdiabetes.ca

Back up SC: Hector Com MD and Glaiza Erfe MD

Summary: A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecglipton in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)


Hypothesis: AZD5004 versus placebo to determine whether AZD5004 on a background of SGLT2i (dapagliflozin) as GDMT and other standard of care therapies for CKD will be superior in lowering the incidence of a composite of 50% decline in eGFR, ESKD or all-cause mortality in a broad population of patients with CKD with and without T2DM

Eligible Participants include:

- Male or female > 18 yrs of age
- BMI > 23 kg/m²
- A1c ≤ 10%
- UACR 3.39-22.6 mg/mmol with eGFR 20-40 (capped at 10%)
- UACR > 22.6 with eGFR 20-60
- UACR > 56.5 with eGFR 61-90 (capped at 10%)
- On stable ACEi or ARB
- No GLP-1 RA within 90 days of screening

Treatment course and duration: The estimated maximum study follow-up for participants is approximately 2 to 4.5 years.

Odds of receiving active drug are: 1:1 65 mg AZD5004 vs PBO



Study documents:

[Protocol](#)

Short URL = <https://bit.ly/4tJFHcm>